Beta Bionics Form 4 — 10b5-1 Sales and $5.10 Option Grants for CCO

Rhea-AI Filing Summary

Mark Hopman, Chief Commercial Officer of Beta Bionics, Inc. (BBNX), reported multiple option grants and open-market sales on 09/04/2025 and 09/05/2025. The filings show option awards exercisable at $5.10 and acquisitions of underlying common stock: 656, 4,093 and 11,411 option shares were added, increasing option holdings to 66,428; 33,136; and 21,725 respectively. Concurrently, 18,229 common shares were sold under a Rule 10b5-1 plan (6,818 at a weighted average $19.9736 and 11,411 at $20.564162). Following these transactions Hopman directly beneficially owned 31,215 common shares. Vesting schedules for the options are specified, with some vesting monthly from 09/14/2023 and others following a one-year cliff from 03/20/2023.

Positive

• Sales executed under a Rule 10b5-1 plan, indicating a pre-established, compliant trading program
• Low strike option grants at $5.10 increase long-term incentive alignment with shareholders
• Detailed vesting schedules disclosed, supporting retention and governance transparency

Negative

• Net reduction in direct holdings to 31,215 shares after reported sales
• Material amount of shares sold (18,229) may reduce insider skin in the game in the short term

Insights

Financial Analyst

TL;DR: Insider executed planned sales while receiving low-strike options, leaving modest direct ownership—routine, limited market impact.

The transactions combine option grants exercisable at a $5.10 strike with contemporaneous sales under a pre-established 10b5-1 plan at ~$20 per share. The grants increase long-term incentive exposure via options that vest over multi-year schedules, aligning executive pay with long-term share performance. The 18,229-share sale reduces direct holdings to 31,215, but sales were executed pursuant to a documented plan, limiting signaling of opportunistic timing. For investors this appears as standard compensation and liquidity activity rather than a material change to control or ownership.

Corporate Governance Expert

TL;DR: Use of a Rule 10b5-1 plan and detailed vesting terms reflects governance and internal controls around insider transactions.

The filing explicitly states shares were sold under a Rule 10b5-1 plan adopted May 13, 2025, which provides an affirmative defense under insider trading rules if properly structured. Option vesting schedules are disclosed, including a one-year cliff and 48-month monthly vesting for different grants, which supports retention and aligns management incentives. Documentation and signature by an attorney-in-fact are present, indicating procedural compliance. Overall this is a routine insider compensation and liquidity event with appropriate governance mechanics.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hopman Mark

(Last) (First) (Middle)

C/O BETA BIONICS, INC.

11 HUGHES

(Street)

IRVINE CA 92618

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Beta Bionics, Inc. [ BBNX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Commercial Officer

3. Date of Earliest Transaction (Month/Day/Year)
09/04/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/04/2025		M		656	A	$5.1	33,940	D
Common Stock	09/04/2025		M		4,093	A	$5.1	38,033	D
Common Stock	09/04/2025		S(1)		6,818	D	$19.9736(2)	31,215	D
Common Stock	09/05/2025		M		11,411	A	$5.1	42,626	D
Common Stock	09/05/2025		S(1)		11,411	D	$20.5641(3)	31,215	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$5.1	09/04/2025		M			656	(4)	07/26/2033	Common Stock	656	$0	66,428	D
Employee Stock Option (right to buy)	$5.1	09/04/2025		M			4,093	(5)	09/13/2033	Common Stock	4,093	$0	33,136	D
Employee Stock Option (right to buy)	$5.1	09/05/2025		M			11,411	(5)	09/13/2033	Common Stock	11,411	$0	21,725	D

Explanation of Responses:

1. Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on May 13, 2025.

2. The weighted average sale price for the transaction reported was $19.9736 and the range of prices were between $19.43 and $20.10. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

3. The weighted average sale price for the transaction reported was $20.564162 and the range of prices were between $20.29 and $20.80. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

4. One-fourth of the shares subject to this option shall vest one year after March 20, 2023, and thereafter 1/36th of the shares subject to this option shall vest on each monthly anniversary thereof.

5. The shares subject to this option shall vest in 48 equal monthly installments measured from September 14, 2023.

	/s/ Stephen Feider, Attorney-in-Fact	09/08/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Mark Hopman (BBNX) report on the Form 4?

The Form 4 reports option awards exercisable at $5.10 and open-market sales of 6,818 and 11,411 shares on 09/04/2025 and 09/05/2025, respectively.

Were the share sales by the reporting person part of a pre-established plan?

Yes. The filings state the shares were sold pursuant to a Rule 10b5-1 plan adopted May 13, 2025.

What were the weighted average sale prices for the reported transactions?

The weighted average sale prices were $19.9736 for the 09/04/2025 sale and $20.564162 for the 09/05/2025 sale.

How many shares does Mark Hopman beneficially own after these transactions?

Following the reported transactions, the Form 4 shows 31,215 common shares beneficially owned.

What are the vesting terms for the options reported?

One option vests one-fourth after one year from 03/20/2023 then monthly thereafter; other options vest in 48 equal monthly installments measured from 09/14/2023.